Steven Cohen Theravance Biopharma, Inc. Transaction History
Point72 Asset Management, L.P.
- $44.6 Billion
- Q2 2025
A detailed history of Steven Cohen (Point72 Asset Management, L.P.) transactions in Theravance Biopharma, Inc. stock. As of the latest transaction made, Point72 Asset Management, L.P. holds 12,692 shares of TBPH stock, worth $181,622. This represents 0.0% of its overall portfolio holdings.
Number of Shares
12,692Holding current value
$181,622% of portfolio
0.0%Shares
5 transactions
Others Institutions Holding TBPH
# of Institutions
140Shares Held
48.7MCall Options Held
0Put Options Held
11.6K-
Madison Avenue Partners, LP New York, NY9.51MShares$136 Million11.23% of portfolio
-
Weiss Asset Management LP Boston, MA7.46MShares$107 Million1.24% of portfolio
-
Newtyn Management, LLC New York, NY4.95MShares$70.8 Million10.56% of portfolio
-
Black Rock Inc. New York, NY3.78MShares$54.1 Million0.0% of portfolio
-
Irenic Capital Management LP New York, NY2.76MShares$39.5 Million4.49% of portfolio
About Theravance Biopharma, Inc.
- Ticker TBPH
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 66,782,400
- Market Cap $956M
- Description
- Theravance Biopharma, Inc., a biopharmaceutical company, discovers, develops, and commercializes respiratory medicines in the United States, Europe, and Asia. The company offers YUPELRI, a once-daily, nebulized long-acting muscarinic antagonist used for the treatment of chronic obstructive pulmonary disease (COPD). Its product portfolio also inc...